Author:
Šlegerová Lenka,Kopečková Kateřina
Funder
Ministerstvo Školství, Mládeže a Tělovýchovy
Univerzita Karlova v Praze
Subject
Health Policy,Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Economics, Econometrics and Finance (miscellaneous)
Reference39 articles.
1. HER2-positive breast cancer;Loibl;Lancet,2017
2. Breast Cancer: Innovations in Research and Management;Veronesi,2017
3. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer;Swain;N Engl J Med,2015
4. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study;Swain;Lancet Oncol,2020
5. Cost-effectiveness of pertuzumab in human epidermal growth factor receptor 2–positive metastatic breast cancer;Durkee;J Clin Oncol,2016
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献